Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

    Virtual Booth

    Contact Supplier

    Coral

    Virtual Booth

    Contact Supplier

    ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

    Virtual Booth

    Contact Supplier

    Menu

    Omalizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 974,765Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 22Xolair

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2019 Revenue in Millions : 2,028

    2018 Revenue in Millions : 1,969

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Xolair

    Omalizumab

    arrow
    OPRD
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    OPRD
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2020 Revenue in Millions : 1,251

    2019 Revenue in Millions : 1,173

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 2,121

    2019 Revenue in Millions : 2,194

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2021 Revenue in Millions : 1,428

    2020 Revenue in Millions : 1,251

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 2,090

    2020 Revenue in Millions : 2,018

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 1,365

    2021 Revenue in Millions : 1,428

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 2,414

    2021 Revenue in Millions : 2,090

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 2,525

    2022 Revenue in Millions : 2,414

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 1,463

    2022 Revenue in Millions : 1,365

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Xolair

    Omalizumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2024 Revenue in Millions : 2,721

    2023 Revenue in Millions : 2,525

    Growth (%) : 8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF